Page 258 - Read Online
P. 258

Bosch et al. Neuroimmunol Neuroinflammation 2017;4:258-9         Neuroimmunology and
           DOI: 10.20517/2347-8659.2017.48
                                                                                  Neuroinflammation

                                                                                                www.nnjournal.net
            Letter to Editor                                                                    Open Access

           Transcranial magnetic stimulation for

           schizophrenia: potential and risks



           Peggy Bosch , Sujung Yeo , Heike Staudte , Pia Barisch , Sabina Lim , Maurits van den Noort 5,6
                       1,2
                                   3
                                                                        5
                                                 1
                                                            1,4
           1 Psychiatric Research Group, LVR-Klinik Bedburg-Hau, 47511 Bedburg-Hau, Germany.
           2 Centre for Cognition, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, 6500 GL Nijmegen, Gelderland, The
           Netherlands.
           3 College of Korean Medicine, Sang Ji University, Wonju 26339, South Korea.
           4 Institute of Experimental Psychology, Heinrich Heine University, 40225 Düsseldorf, Germany.
           5 Research Group of Pain and Neuroscience, Kyung Hee University, Seoul 130-701, South Korea.
           6 Brussels Institute for Applied Linguistics, Vrije Universiteit Brussel, 1050 Brussels, Belgium.
           Correspondence to: Dr. Peggy Bosch, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, Montessorilaan 3, 6500
           GL Nijmegen, Gelderland, The Netherlands. E-mail: p.bosch@donders.ru.nl; Prof. Maurits van den Noort, Research Group of Pain and Neuroscience,
           Kyung Hee University, #47 Gyeonghuidae-Gil, Dongdaemun-Gu, Seoul 130-701, South Korea. E-mail: info@mauritsvandennoort.com
           How to cite this article: Bosch P, Yeo S, Staudte H, Barisch P, Lim S, van den Noort M. Transcranial magnetic stimulation for schizophrenia:
           potential and risks. Neuroimmunol Neuroinflammation 2017;4:258-9.

           Article history:  Received: 9 Sep 2017      Accepted: 11 Sep 2017      Published: 6 Dec 2017

           Recently, transcranial magnetic stimulation (TMS)   as was recently concluded in a large systematic
                                                                                                            [2]
           has increasingly been used to investigate the      review of forty-one trials by Dougall and colleagues .
           neurobiology of schizophrenia. In those studies,   Studies differ in numerous variables, for example, the
           researchers applied TMS in combination with motor   stimulation intensity or length, the areas of the brain
           evoked potentials (TMS/MEPs) and high density      that are stimulated, and the design of the same TMS
                                                    [1]
           electroencephalograms (TMS/hd-EEG) . The           condition. Those variables could have great impact on
           studies revealed significant impairments in cortical   the effects of TMS in the studied population. Therefore,
           excitability, inhibition, and oscillatory activity, which are   better, well-developed TMS studies that test specific
           more prominent in the frontal brain areas, in patients   underlying neurobiological working mechanisms in
           suffering from schizophrenia compared to healthy   schizophrenia are warranted. Moreover, schizophrenia
                  [1]
           controls . Future TMS studies may help explain the   is not a static, but rather a dynamic, disorder; therefore,
           underlying neurobiology of schizophrenia, and TMS   TMS studies should focus more on patients with different
           may help monitor and perhaps further optimize the   stages of schizophrenia, i.e. patients experiencing
           effectiveness of treatment interventions in patients with   their first episode of schizophrenia versus patients with
           this disease. However, despite the potential of using   chronic schizophrenia.
           TMS in the investigation of the underlying neurobiology
           of schizophrenia, three critical notes are essential.  Second, within the studies, insufficient attention has
                                                              been paid to the safety of using TMS on patients with
           First, so far, TMS studies on schizophrenia have   schizophrenia. This is remarkable considering that
           been neither robust, consistent, nor standardized   a vivid discussion of the risks of using TMS to treat
                                                                                        [3]
           enough and have had high risks of publication bias,   psychiatric patients is ongoing . From the literature, for
                                                                                              Quick Response Code:
                       This is an open access article licensed under the terms of Creative Commons Attribution 4.0 International
                       License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
            and reproduction in any medium, as long as the original author is credited and the new creations are licensed under the
            identical terms.
            For reprints contact: service@oaepublish.com

            258   © The author(s) 2017                                                                                                                                            www.oaepublish.com
   253   254   255   256   257   258   259   260   261   262   263